Summary of Product Characteristics
last updated on the eMC:
31/03/2009
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 31/03/2009 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
-
Change to section 4.8 - Undesirable Effects
-
Change to section 5.1 - Pharmacodynamic Properties
-
Change to section 6.1 - List of Excipients
|
| Date of revision of text on the SPC: 19-Jun-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
|
Section 4.4 - Deleted "Thiomersal (an organomercuric compound) has been used in the manufacturing process of this medicinal product and residues of it are present in the final product. Therefore, sensitisation reactions may occur."
Section 4.8 - Added "The current formulation of Twinrix does not contain thiomersal (an organomercuric compound) or any preservative. In a clinical study conducted with the current formulation, the incidence of pain, redness, swelling, fatigue, gastro-enteritis, headache and fever was comparable to the incidence observed with the former thiomersal and preservative containing vaccine formulation. The following undesirable effects have been reported following the widespread use of the former formulation."
Section 5.1 - Added "These data were generated with the former Twinrix formulation containing thiomersal and a preservative. A clinical study conducted with the current formulation of Twinrix in adults showed that the current formulation elicited similar seroprotection and seroconversion rates as compared to the former formulation."
Section 6.1 - Deleted "Phenoxyethanol"
|
|
Updated on 17/02/2009 and displayed until 31/03/2009
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
-
Change to section 4.8 - Undesirable Effects
-
Change to section 5.1 - Pharmacodynamic Properties
-
Change to section 6.1 - List of Excipients
|
| Date of revision of text on the SPC: 19-Jun-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Section 4.4 - Added "Thiomersal (an organomercuric compound) has been used in the manufacturing process of this medicinal product and residues of it are present in the final product. Therefore, sensitisation reactions may occur."
Section 4.8 - Deleted "The current formulation of Twinrix does not contain thiomersal (an organomercuric compound) or any preservative. In a clinical study conducted with the current formulation, the incidence of pain, redness, swelling, fatigue, gastro-enteritis, headache and fever was comparable to the incidence observed with the former thiomersal and preservative containing vaccine formulation. The following undesirable effects have been reported following the widespread use of the former formulation."
Section 5.1 - Deleted "These data were generated with the former Twinrix formulation containing thiomersal and a preservative. A clinical study conducted with the current formulation of Twinrix in adults showed that the current formulation elicited similar seroprotection and seroconversion rates as compared to the former formulation."
Section 6.1 - Added "Phenoxyethanol"
|
|
Updated on 10/11/2008 and displayed until 17/02/2009
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
-
Change to section 4.6 - Pregnancy and Lactation
-
Change to section 5.3 - Preclinical Safety Data
|
| Date of revision of text on the SPC: 19-Jun-2008 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
Section 4.4 - Additional information on obesity for Twinrix Adult only
Section 4.6 - New section on pregnancy for both vaccines
Section 5.3 - Addition of '(see section 4.6)' for both vaccines
|
|
Updated on 04/12/2006 and displayed until 10/11/2008
|
Reasons for adding or updating:
|
-
Change to section 1 -Name of the Medicinal product
-
Change to section 2 - Qualitative and quantitative composition
-
Change to section 3 - Pharmaceutical form
-
Change to section 4.3 - Contraindications
-
Change to section 4.6 - Pregnancy and Lactation
-
Change to section 4.8 - Undesirable Effects
-
Change to section 5.1 - Pharmacodynamic Properties
-
Change to section 5.3 - Preclinical Safety Data
-
Change to section 6.1 - List of Excipients
-
Change to section 6. 4 - Special Precautions for Storage
-
Change to section 6. 6 - Instructions for use, handling and disposal
-
Change to section 9 - Date of first Authorisation/renewal of the Authorisation
-
Change to section 10 date of revision of the text
|
| Date of revision of text on the SPC: 08/2006 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
|
For further information, please contact GlaxoSmithKline on +44 (0)800 221 441
|
|
Updated on 01/11/2002 and displayed until 04/12/2006
|
Reasons for adding or updating:
|
-
Improved Electronic Presentation
|
|
Updated on 23/10/2002 and displayed until 01/11/2002
|
Reasons for adding or updating:
|
-
Improved Electronic Presentation
|
|
Updated on 26/09/2001 and displayed until 23/10/2002
|
Reasons for adding or updating:
|
-
Change to section 4.2 - Posology and Method of Administration
-
Change to section 4.8 - Undesirable Effects
-
Change to section 5.1 - Pharmacodynamic Properties
|
|
Updated on 05/08/2001 and displayed until 26/09/2001
|
Reasons for adding or updating:
|
-
Transferred from eMC version 1
|
|
Updated on 06/09/1999 and displayed until 05/08/2001
|
Reasons for adding or updating:
|
|
|
|